Pelvic Exenteration for Recurrent Endometrial Cancer: A 15-Year Monocentric Retrospective Study.
multivisceral surgery
pelvic exenteration
recurrent endometrial cancer
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
26 Sep 2023
26 Sep 2023
Historique:
received:
03
08
2023
revised:
22
09
2023
accepted:
24
09
2023
medline:
14
10
2023
pubmed:
14
10
2023
entrez:
14
10
2023
Statut:
epublish
Résumé
Treatment options for recurrent endometrial adenocarcinoma are limited. In those cases, secondary surgical procedures such as pelvic exenteration form the only possible curative approach. The aim of this study was analyzing the outcomes of patients who underwent pelvic exenteration during the treatment of recurrent endometrial cancer intending to identify prognostic factors. More than 300 pelvic exenterations were performed. Fifteen patients were selected that received pelvic exenteration for recurrent endometrial adenocarcinoma. Data regarding patient characteristics, indication for surgery, complete cytoreduction, tumor grading and p53- and L1CAM-expression were collected and statistically evaluated. Univariate Cox regression was performed to identify predictive factors for long-term survival. The mean survival after pelvic exenteration for the whole patient population was 22.7 months, with the longest survival reaching up to 69 months. Overall survival was significantly longer for patients with a curative treatment intention (
Identifiants
pubmed: 37835424
pii: cancers15194725
doi: 10.3390/cancers15194725
pmc: PMC10571688
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int J Gynecol Cancer. 2016 May;26(4):716-21
pubmed: 26937752
Br J Cancer. 2023 Mar;128(7):1360-1368
pubmed: 36690721
Eur J Obstet Gynecol Reprod Biol. 2007 Oct;134(2):243-8
pubmed: 16950559
Int J Gynecol Cancer. 2012 Jun;22(5):889-96
pubmed: 22617477
ANZ J Surg. 2022 Nov;92(11):2822-2828
pubmed: 35490337
Gynecol Oncol. 2011 Jul;122(1):14-8
pubmed: 21444105
In Vivo. 2019 Nov-Dec;33(6):2205-2210
pubmed: 31662557
ANZ J Surg. 2017 Jul;87(7-8):582-586
pubmed: 27990753
Gynecol Oncol. 2010 Jul;118(1):14-8
pubmed: 20434198
Gynecol Oncol. 2004 Jun;93(3):610-4
pubmed: 15196852
Gynecol Oncol. 2021 Aug;162(2):268-276
pubmed: 34090704
Gynecol Oncol Rep. 2021 Mar 31;36:100757
pubmed: 33898694
Cancer. 1948 Jul;1(2):177-83
pubmed: 18875031
Colorectal Dis. 2020 Oct;22(10):1216
pubmed: 33099877
Cochrane Database Syst Rev. 2014 Feb 04;(2):CD010449
pubmed: 24497188
Onco Targets Ther. 2023 Jun 02;16:359-369
pubmed: 37288137
Gynecol Oncol. 2017 Aug;146(2):327-333
pubmed: 28511869
J Surg Oncol. 2010 May 1;101(6):507-12
pubmed: 20401918
Gynecol Oncol. 2022 May;165(2):393-400
pubmed: 35331571
Gynecol Oncol Rep. 2016 Dec 29;19:39-41
pubmed: 28070552
Ann Oncol. 2018 May 1;29(5):1180-1188
pubmed: 29432521
Gynecol Oncol. 1996 Feb;60(2):288-91
pubmed: 8631553
Int J Gynecol Cancer. 2014 Jun;24(5):880-4
pubmed: 24685828
Mod Pathol. 2016 Feb;29(2):174-81
pubmed: 26743472
Acta Obstet Gynecol Scand. 2010;89(2):279-83
pubmed: 19916881
Gynecol Obstet Invest. 2022;87(3-4):191-199
pubmed: 35793638
Int J Gynecol Cancer. 2021 Jan;31(1):12-39
pubmed: 33397713
Gynecol Oncol. 2012 Jan;124(1):42-7
pubmed: 22014627
Ann Surg Oncol. 2019 Feb;26(2):523-530
pubmed: 30539489
Cancers (Basel). 2021 Mar 23;13(6):
pubmed: 33806979
J Natl Compr Canc Netw. 2023 Feb;21(2):217-226
pubmed: 36791759
Gynecol Oncol. 2014 Sep;134(3):546-51
pubmed: 25014540
Gynecol Oncol. 1999 Oct;75(1):99-102
pubmed: 10502433
J Clin Oncol. 2023 Jun 1;41(16):2904-2910
pubmed: 37058687
Ann Surg Oncol. 2021 May;28(5):2790-2800
pubmed: 33105501
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398
Fukushima J Med Sci. 2022 Dec 21;68(3):191-195
pubmed: 36351631
Eur J Surg Oncol. 2006 Oct;32(8):859-65
pubmed: 16690243
Gynecol Oncol. 2023 Jul;174:231-238
pubmed: 37236032
Eur J Surg Oncol. 2019 Oct;45(10):1787-1795
pubmed: 31255441